BioSpace News Archive

Whether you’re looking for a new job, negotiating for more pay or responsibility, or seeking to make the transition to a management or leadership position, your presence on social media makes up a large component of your overall professional “brand.”

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.

Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.

Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.

Allecra Therapeutics released positive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria.

Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

Adagene Inc. announced a $50 million Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.

Stoke Therapeutics, Inc., a biotechnology company developing therapeutics that increase gene expression to treat a wide array of diseases caused by genetic insufficiency, will present research on its first-in-class medicines today at the Oligonucleotide & Peptide Therapeutics Boston Conference in Cambridge, Mass.

Boehringer Ingelheim, KMOH, and ZNWT establish a vaccine joint venture targeting foot-and-mouth disease control and prevention in China; The vaccine manufacturing project is located at the Airport New City in Xi’an with a total investment of 840 million yuan (around €108 million); The venture will introduce the world’s leading vaccine technology and expertise against foot-and-mouth disease in a bid to shape the future market in China